
BioDelivery Sciences International, Inc. – NASDAQ:BDSI
BioDelivery Sciences International stock price today
BioDelivery Sciences International stock price monthly change
BioDelivery Sciences International stock price quarterly change
BioDelivery Sciences International stock price yearly change
BioDelivery Sciences International key metrics
Market Cap | 577.05M |
Enterprise value | 442.03M |
P/E | 6.81 |
EV/Sales | 5.25 |
EV/EBITDA | 16.08 |
Price/Sales | 6.55 |
Price/Book | 2.93 |
PEG ratio | 0.03 |
EPS | 0.85 |
Revenue | 166.70M |
EBITDA | 44.54M |
Income | 84.86M |
Revenue Q/Q | 2.34% |
Revenue Y/Y | 6.54% |
Profit margin | 100.82% |
Oper. margin | 44.11% |
Gross margin | 72.23% |
EBIT margin | 44.11% |
EBITDA margin | 26.72% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBioDelivery Sciences International stock price history
BioDelivery Sciences International stock forecast
BioDelivery Sciences International financial statements
Mar 2021 | 41.02M | 5.23M | 12.77% |
---|---|---|---|
Jun 2021 | 41.43M | 9.06M | 21.87% |
Sep 2021 | 41.09M | 6.66M | 16.23% |
Dec 2021 | 43.15M | 63.89M | 148.05% |
2021-08-04 | 0.05 | 0.09 |
---|---|---|
2021-11-03 | 0.06 | 0.07 |
2022-03-09 | 0.02 | 0.62 |
Mar 2021 | 242130000 | 133.27M | 55.04% |
---|---|---|---|
Jun 2021 | 250327000 | 136.40M | 54.49% |
Sep 2021 | 256070000 | 133.29M | 52.05% |
Dec 2021 | 324596000 | 136.77M | 42.14% |
Mar 2021 | 11.09M | -296K | -5.94M |
---|---|---|---|
Jun 2021 | 9.23M | -119K | -5.69M |
Sep 2021 | 6.96M | -6.45M | -19.64M |
Dec 2021 | 13.74M | -1K | -148K |
BioDelivery Sciences International alternative data
Aug 2023 | 200 |
---|---|
Sep 2023 | 200 |
Oct 2023 | 200 |
Nov 2023 | 200 |
Dec 2023 | 200 |
Jan 2024 | 200 |
Feb 2024 | 200 |
Mar 2024 | 200 |
Apr 2024 | 200 |
May 2024 | 200 |
Jun 2024 | 200 |
Jul 2024 | 200 |
BioDelivery Sciences International other data
Period | Buy | Sel |
---|---|---|
May 2021 | 315500 | 0 |
Nov 2021 | 483800 | 10000 |
Dec 2021 | 18587 | 0 |
Feb 2022 | 0 | 18541 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | BAILEY JEFFREY ALLEN director, officer.. | Restricted Stock Units | 5,333 | N/A | N/A | ||
Option | BAILEY JEFFREY ALLEN director, officer.. | Common Stock | 5,333 | N/A | N/A | ||
Sale | VOLLINS JAMES officer: General .. | Common Stock | 18,541 | $3.6 | $66,748 | ||
Option | PLESHA SCOTT M. officer: Presiden.. | Restricted Stock Units | 45,253 | N/A | N/A | ||
Option | PLESHA SCOTT M. officer: Presiden.. | Common Stock | 24,203 | N/A | N/A | ||
Option | VOLLINS JAMES officer: General .. | Restricted Stock Units | 28,413 | N/A | N/A | ||
Option | VOLLINS JAMES officer: General .. | Common Stock | 12,137 | N/A | N/A | ||
Option | SMITH THOMAS B officer: Chief Medical Officer | Restricted Stock Units | 32,576 | N/A | N/A | ||
Option | SMITH THOMAS B officer: Chief Medical Officer | Common Stock | 15,215 | N/A | N/A | ||
Option | PLESHA SCOTT M. officer: Presiden.. | Common Stock | 21,050 | N/A | N/A |
Patent |
---|
Application Filling date: 7 Feb 2022 Issue date: 21 Jul 2022 |
Application Filling date: 27 Dec 2021 Issue date: 30 Jun 2022 |
Application PATCH DEVICES, METHODS AND APPARATUS FOR FORMING, AND TESTING PHARMACEUTICAL AGENT DELIVERY PATCH DEVICES Filling date: 25 Dec 2021 Issue date: 16 Jun 2022 |
Application Filling date: 15 Sep 2021 Issue date: 10 Mar 2022 |
Application Filling date: 10 Oct 2020 Issue date: 20 Jan 2022 |
Application Filling date: 22 Mar 2021 Issue date: 9 Sep 2021 |
Application Filling date: 12 Feb 2021 Issue date: 19 Aug 2021 |
Application Filling date: 30 Jan 2021 Issue date: 22 Jul 2021 |
Application Filling date: 16 Jul 2020 Issue date: 7 Jan 2021 |
Application Filling date: 30 Apr 2020 Issue date: 19 Nov 2020 |
Quarter | Transcript |
---|---|
Q3 2021 3 Nov 2021 | Q3 2021 Earnings Call Transcript |
Q2 2021 4 Aug 2021 | Q2 2021 Earnings Call Transcript |
Q4 2020 10 Mar 2021 | Q4 2020 Earnings Call Transcript |
Q2 2020 5 Aug 2020 | Q2 2020 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Scott M. Plesha (1965) Pres & Chief Commercial Officer | $629,460 |
Mr. Jeffrey Allen Bailey (1963) Chief Executive Officer & Director | $599,960 |
Mr. James Vollins J.D. (1969) Gen. Counsel, Chief Compliance Officer & Corporation Sec. | $586,680 |
Dr. Thomas B. Smith FAAFP, M.D. (1961) Chief Medical Officer | $570,060 |
-
What's the price of BioDelivery Sciences International stock today?
One share of BioDelivery Sciences International stock can currently be purchased for approximately $5.59.
-
When is BioDelivery Sciences International's next earnings date?
Unfortunately, BioDelivery Sciences International's (BDSI) next earnings date is currently unknown.
-
Does BioDelivery Sciences International pay dividends?
No, BioDelivery Sciences International does not pay dividends.
-
How much money does BioDelivery Sciences International make?
BioDelivery Sciences International has a market capitalization of 577.05M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 6.54% to 166.7M US dollars. BioDelivery Sciences International earned 84.86M US dollars in net income (profit) last year or $0.62 on an earnings per share basis.
-
What is BioDelivery Sciences International's stock symbol?
BioDelivery Sciences International, Inc. is traded on the NASDAQ under the ticker symbol "BDSI".
-
What is BioDelivery Sciences International's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of BioDelivery Sciences International?
Shares of BioDelivery Sciences International can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are BioDelivery Sciences International's key executives?
BioDelivery Sciences International's management team includes the following people:
- Mr. Scott M. Plesha Pres & Chief Commercial Officer(age: 60, pay: $629,460)
- Mr. Jeffrey Allen Bailey Chief Executive Officer & Director(age: 62, pay: $599,960)
- Mr. James Vollins J.D. Gen. Counsel, Chief Compliance Officer & Corporation Sec.(age: 56, pay: $586,680)
- Dr. Thomas B. Smith FAAFP, M.D. Chief Medical Officer(age: 64, pay: $570,060)
-
How many employees does BioDelivery Sciences International have?
As Jul 2024, BioDelivery Sciences International employs 200 workers.
-
When BioDelivery Sciences International went public?
BioDelivery Sciences International, Inc. is publicly traded company for more then 23 years since IPO on 25 Jul 2002.
-
What is BioDelivery Sciences International's official website?
The official website for BioDelivery Sciences International is bdsi.com.
-
Where are BioDelivery Sciences International's headquarters?
BioDelivery Sciences International is headquartered at 4131 Parklake Ave Ste 225, Raleigh, NORTH CAROLINA.
-
How can i contact BioDelivery Sciences International?
BioDelivery Sciences International's mailing address is 4131 Parklake Ave Ste 225, Raleigh, NORTH CAROLINA and company can be reached via phone at +1 919 582 9050.
BioDelivery Sciences International company profile:

BioDelivery Sciences International, Inc.
bdsi.comNASDAQ
200
Drug Manufacturers - Specialty & Generic
Healthcare
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.
Raleigh, NORTH CAROLINA 27612
CIK: 0001103021
ISIN: US09060J1060
CUSIP: 09060J106